FDA approves agent for RA patients who do not respond to methotrexate


FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.